NovaBay Pharmaceuticals (NBY) EBIAT (2016 - 2025)
NovaBay Pharmaceuticals (NBY) has disclosed EBIAT for 16 consecutive years, with -$1.3 million as the latest value for Q3 2025.
- On a quarterly basis, EBIAT fell 6.68% to -$1.3 million in Q3 2025 year-over-year; TTM through Sep 2025 was $4.1 million, a 161.85% increase, with the full-year FY2024 number at -$7.2 million, down 17.33% from a year prior.
- EBIAT was -$1.3 million for Q3 2025 at NovaBay Pharmaceuticals, up from -$1.9 million in the prior quarter.
- In the past five years, EBIAT ranged from a high of $7.7 million in Q1 2025 to a low of -$8.2 million in Q4 2022.
- A 5-year average of -$1.3 million and a median of -$1.6 million in 2024 define the central range for EBIAT.
- Peak YoY movement for EBIAT: crashed 5093.67% in 2022, then soared 338.64% in 2025.
- NovaBay Pharmaceuticals' EBIAT stood at -$158000.0 in 2021, then plummeted by 5093.67% to -$8.2 million in 2022, then surged by 92.53% to -$613000.0 in 2023, then skyrocketed by 41.6% to -$358000.0 in 2024, then plummeted by 261.17% to -$1.3 million in 2025.
- Per Business Quant, the three most recent readings for NBY's EBIAT are -$1.3 million (Q3 2025), -$1.9 million (Q2 2025), and $7.7 million (Q1 2025).